What Are Peptides? Understanding the Science, Potential and Changing Landscape

Peptides have become an increasingly visible topic in medicine, research and wellness. You may have encountered names such as BPC-157, MOTS-c or Semax online, while other peptide-based medications—including insulin and certain GLP-1 therapies—have been part of established medical care.

In fact, “peptide” describes a broad category of substances, not a single type of treatment. And while some peptides are well studied and used in FDA-approved medications, others remain investigational, with limited human clinical evidence.

Recent discussions at the U.S. Food and Drug Administration (FDA) have brought renewed attention to several of these investigational peptides—and to the potential role of traditional pharmacy compounding in the future.

What Are Peptides?

Peptides are short chains of amino acids, the same building blocks that make up proteins. Many peptides occur naturally in the human body, where they can function as signaling molecules involved in biological processes.

Their functions vary considerably depending on their structure. That distinction is important: evidence about one peptide cannot be assumed to apply to another.

Scientists have successfully translated some peptide biology into medications. Insulin is one familiar example, and several newer medications are also peptide-based. At the same time, researchers continue to investigate other peptides for potential applications ranging from inflammation and wound healing to metabolic and neurological conditions.

For many of these investigational peptides, however, early laboratory or animal research has progressed further than human clinical research. Questions may remain about effective dosing, long-term safety, stability and potential immune responses.

Why Is There So Much Interest in Peptides?

Part of the interest comes from the way peptides can interact with specific biological pathways. This has made them an active area of scientific research and drug development.

However, “potential” is an important word.

Promising laboratory findings do not necessarily mean that a substance has been proven safe or effective in people. Some peptides promoted online have little high-quality human clinical evidence supporting the claims made about them.

That makes the source of information—and of any product—a particularly important consideration. Products sold online as “research chemicals” may exist outside the safeguards associated with a licensed pharmacy. Their identity, concentration, purity, sterility and storage conditions may be difficult for a consumer to verify.

Where Does Compounding Fit In?

Traditional pharmacy compounding serves patients who have a clinical need that cannot be met by an available manufactured medication. A state-licensed 503A compounding pharmacy like Pharmacy Solutions can prepare a customized medication for an individually identified patient according to a valid prescription.

Compounded medications are not FDA-approved. Unlike an FDA-approved drug, a compounded preparation does not undergo FDA’s premarket review for safety, effectiveness and quality.

Federal law also establishes requirements governing which bulk drug substances a 503A pharmacy can use. Generally, an ingredient must meet an applicable USP or National Formulary monograph, be a component of an FDA-approved drug, or appear on FDA’s 503A Bulks List, along with satisfying other applicable requirements.

That last pathway is at the center of the current peptide discussion.

What Happened at the Recent FDA Advisory Committee Meeting?

On July 23 and 24, 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) considered seven peptide-related bulk drug substances for possible inclusion on the 503A Bulks List.

The committee recommended six for inclusion: BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. The committee did not recommend Emideltide, also known as DSIP.

Those votes are significant—but they are not FDA approval.

PCAC is an advisory committee. Its recommendations help inform FDA decision-making but are not binding. A favorable vote also does not establish that a peptide is safe or effective for a particular medical condition, nor does the vote by itself add the substance to the 503A Bulks List.

FDA must take additional regulatory action before any change becomes official.

The Seven Peptides Under Review

Here’s a brief look at what FDA specifically evaluated. These are areas of investigation considered during the regulatory review, not FDA-approved indications.

BPC-157

BPC-157 has attracted considerable attention in research related to tissue response and healing. For the PCAC review, FDA evaluated BPC-157 in relation to ulcerative colitis. FDA reviewers identified significant limitations in the available evidence, including insufficient information to establish effectiveness and limited human safety data.

KPV

KPV is a short peptide that has been investigated for its potential relationship to inflammatory processes. FDA’s review considered proposed uses involving wound healing and inflammatory conditions.

TB-500

TB-500 is a peptide-related substance that has generated interest around tissue repair and recovery. For purposes of the PCAC review, FDA evaluated its proposed use in wound healing.

MOTS-c

MOTS-c is a mitochondrial-derived peptide being studied in connection with metabolism and cellular function. FDA evaluated proposed uses involving obesity and osteoporosis. Research into MOTS-c remains an evolving area.

Semax

Semax is a synthetic peptide that has been studied internationally for neurological applications. FDA’s PCAC review considered proposed uses for cerebral ischemia, migraine and trigeminal neuralgia.

Epitalon

Epitalon is a synthetic peptide that has been investigated in areas related to sleep and aging biology. For this review, FDA evaluated its proposed use for insomnia. FDA’s briefing materials noted substantial gaps in human safety information.

Emideltide (DSIP)

Emideltide, often referred to as delta sleep-inducing peptide or DSIP, has been investigated in connection with sleep and other neurological functions. FDA evaluated proposed uses for opioid withdrawal, chronic insomnia and narcolepsy. It was the only one of the seven substances that did not receive a favorable recommendation from the committee.

What Does This Mean for Patients Today?

The July 2026 meeting represents an important development in the regulatory conversation surrounding peptides and compounding, but it should not be interpreted as an endorsement of peptide products currently marketed to consumers.

The committee’s recommendations do not mean these six peptides have become FDA-approved drugs, nor do they automatically make them available for compounding. Additional FDA action is necessary.

As research and regulation continue to evolve, patients should be cautious about products sold online or labeled “for research use only.” A substance being widely discussed on social media—or even being the subject of promising early research—is not the same as having established safety and effectiveness in controlled human studies.

At Pharmacy Solutions, we believe emerging therapies should be approached with the same principles that guide responsible personalized medicine: qualified medical oversight, transparent sourcing, appropriate quality standards and clear communication among patients, prescribers and pharmacists.

We are closely following FDA’s review of peptide-related bulk drug substances and will continue to provide updates as the regulatory landscape develops.

Have questions about this or other issues? We’ve got answers.

Ask a Pharmacist

Disclaimer: This article is for educational purposes only and is not medical advice. Always talk with your healthcare provider before starting, stopping or changing any medication, supplement or health plan. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Contact Us
Categories

Tags

compounding pharmacy
personalized medicine
Peptides
Peptide Therapy
503A Compounding
Semax
MOTS-c
FDA
Peptide Research
Epitalon
KPV
TB-500
BPC-157
DSIP

Other Blogs

Secret Link

ATTENTION!

YOUR FORM IS NOT SUBMITTED

To submit your order, click the “PRINT/SAVE” button located under this pop-up. 

You can save the PDF to your computer to fax at a later date or print it now to fax immediately.  

Fax your order form to 817-860-6083 for processing.

Provider Access Required Create a provider account to view the full resource library, including the drug catalog, order forms and more.

Log In

New to Pharmacy Solutions? Register now